| REGISTERED NUMBER: |
| Strategic Report, Report of the Directors and |
| Financial Statements for the Year Ended 30 November 2025 |
| for |
| Altripan UK Limited |
| REGISTERED NUMBER: |
| Strategic Report, Report of the Directors and |
| Financial Statements for the Year Ended 30 November 2025 |
| for |
| Altripan UK Limited |
| Altripan UK Limited (Registered number: 06245964) |
| Contents of the Financial Statements |
| for the year ended 30 November 2025 |
| Page |
| Company Information | 1 |
| Strategic Report | 2 |
| Report of the Directors | 3 |
| Report of the Independent Auditors | 5 |
| Income Statement | 8 |
| Other Comprehensive Income | 9 |
| Balance Sheet | 10 |
| Statement of Changes in Equity | 11 |
| Cash Flow Statement | 12 |
| Notes to the Cash Flow Statement | 13 |
| Notes to the Financial Statements | 14 |
| Altripan UK Limited |
| Company Information |
| for the year ended 30 November 2025 |
| Directors: |
| Secretary: |
| Registered office: |
| Registered number: |
| Senior statutory auditor: |
| Auditors: |
| Statutory Auditor |
| Certified Accountants |
| Unit 2 Foley Works |
| Foley Trading Estate |
| Hereford |
| Herefordshire |
| HR1 2SF |
| Altripan UK Limited (Registered number: 06245964) |
| Strategic Report |
| for the year ended 30 November 2025 |
| The directors present their strategic report for the year ended 30 November 2025. |
| Review of business |
| The principal activity of the company was that of sale of timber based products. The directors do not plan to change these activities in the foreseeable future. |
| Development and performance |
| The directors are happy with this year's figures. In this current financial period we continue to see an improvement. |
| The company uses the following Key Performance Indicators to measure its ongoing performance:- |
| - gross profit and contribution percentage - in total, by customer, by product group, by product |
| - distribution, wages, overheads costs as a percentage of sales. |
| Principal risks and uncertainties |
| The directors aim to ensure that financial and compliance risks to the business are minimised through good management. This includes: |
| - ensuring that the risk of exposure to foreign currency losses is minimised |
| - increasing cashflow by adopting invoice discounting |
| - employing sensible credit control procedures to minimise bad debts |
| - forward sales to ensure volume to gain lower margin |
| - ensuring all assets are secure and adequately insured |
| - ensuring products are up to adequate standard by conducting relevant testing |
| On behalf of the board: |
| Altripan UK Limited (Registered number: 06245964) |
| Report of the Directors |
| for the year ended 30 November 2025 |
| The directors present their report with the financial statements of the company for the year ended 30 November 2025. |
| Dividends |
| Interim dividends were paid on a monthly basis during the year on W & S Ordinary shares totalling £205,427 (£4,280 per share (2024: £205,427 (£4,280 per share)). |
| Further interim dividends were paid in March 2025 as below:- |
| Ordinary shares £365,124 (£11,064.33 per share) |
| W Ordinary shares £81,823 (£3,409.29 per share) |
| S Ordinary shares £171,823 (£7,159.29 per share) |
| No final dividend has been declared this year (2024: £nil). |
| Directors |
| The directors shown below have held office during the whole of the period from 1 December 2024 to the date of this report. |
| Other changes in directors holding office are as follows: |
| Statement of directors' responsibilities |
| The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations. |
| Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to: |
| - | select suitable accounting policies and then apply them consistently; |
| - | make judgements and accounting estimates that are reasonable and prudent; |
| - | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
| The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. |
| Statement as to disclosure of information to auditors |
| So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information. |
| Altripan UK Limited (Registered number: 06245964) |
| Report of the Directors |
| for the year ended 30 November 2025 |
| Auditors |
| The auditors, Acre Accountancy Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting. |
| On behalf of the board: |
| Report of the Independent Auditors to the Members of |
| Altripan UK Limited |
| Opinion |
| We have audited the financial statements of Altripan UK Limited (the 'company') for the year ended 30 November 2025 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice). |
| In our opinion the financial statements: |
| - | give a true and fair view of the state of the company's affairs as at 30 November 2025 and of its profit for the year then ended; |
| - | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
| - | have been prepared in accordance with the requirements of the Companies Act 2006. |
| Basis for opinion |
| We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. |
| Conclusions relating to going concern |
| In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. |
| Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. |
| Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. |
| Other information |
| The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon. |
| Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. |
| In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. |
| Opinions on other matters prescribed by the Companies Act 2006 |
| In our opinion, based on the work undertaken in the course of the audit: |
| - | the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
| - | the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements. |
| Report of the Independent Auditors to the Members of |
| Altripan UK Limited |
| Matters on which we are required to report by exception |
| In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors. |
| We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: |
| - | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or |
| - | the financial statements are not in agreement with the accounting records and returns; or |
| - | certain disclosures of directors' remuneration specified by law are not made; or |
| - | we have not received all the information and explanations we require for our audit. |
| Responsibilities of directors |
| As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. |
| In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so. |
| Auditors' responsibilities for the audit of the financial statements |
| Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. |
| The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: |
| We enquired with management about the legal framework that the company operates in. We also enquired about the risk of fraud and whether they were aware of any instances of fraud. |
| We communicated the outcome of this risk assessment with the audit team and planned our audit work accordingly. Our work in these areas is limited to analytical procedures and inspection of relevant documentation. Where a breach of operational regulations is not disclosed to us, or it is not evident from documentation that we receive during the audit, an audit will not detect that breach. |
| A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors. |
| Report of the Independent Auditors to the Members of |
| Altripan UK Limited |
| Use of our report |
| This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed. |
| for and on behalf of |
| Statutory Auditor |
| Certified Accountants |
| Unit 2 Foley Works |
| Foley Trading Estate |
| Hereford |
| Herefordshire |
| HR1 2SF |
| Altripan UK Limited (Registered number: 06245964) |
| Income Statement |
| for the year ended 30 November 2025 |
| 2025 | 2024 |
| Notes | £ | £ |
| TURNOVER |
| Cost of sales | ( |
) | ( |
) |
| GROSS PROFIT |
| Administrative expenses | ( |
) | ( |
) |
| 1,379,573 | 1,863,167 |
| Other operating income |
| OPERATING PROFIT | 4 |
| Interest payable and similar expenses | 5 | ( |
) | ( |
) |
| PROFIT BEFORE TAXATION |
| Tax on profit | 6 | ( |
) | ( |
) |
| PROFIT FOR THE FINANCIAL YEAR |
| Altripan UK Limited (Registered number: 06245964) |
| Other Comprehensive Income |
| for the year ended 30 November 2025 |
| 2025 | 2024 |
| Notes | £ | £ |
| PROFIT FOR THE YEAR |
| OTHER COMPREHENSIVE INCOME | - | - |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR |
| Altripan UK Limited (Registered number: 06245964) |
| Balance Sheet |
| 30 November 2025 |
| 2025 | 2024 |
| Notes | £ | £ |
| FIXED ASSETS |
| Tangible assets | 8 |
| CURRENT ASSETS |
| Stocks | 9 |
| Debtors | 10 |
| CREDITORS |
| Amounts falling due within one year | 11 | ( |
) | ( |
) |
| NET CURRENT ASSETS |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
| CAPITAL AND RESERVES |
| Called up share capital | 15 |
| Retained earnings | 16 |
| SHAREHOLDERS' FUNDS |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| Altripan UK Limited (Registered number: 06245964) |
| Statement of Changes in Equity |
| for the year ended 30 November 2025 |
| Called up |
| share | Retained | Total |
| capital | earnings | equity |
| £ | £ | £ |
| Balance at 1 December 2023 |
| Changes in equity |
| Dividends | - | ( |
) | ( |
) |
| Total comprehensive income | - |
| Balance at 30 November 2024 |
| Changes in equity |
| Dividends | - | ( |
) | ( |
) |
| Total comprehensive income | - |
| Balance at 30 November 2025 |
| Altripan UK Limited (Registered number: 06245964) |
| Cash Flow Statement |
| for the year ended 30 November 2025 |
| 2025 | 2024 |
| Notes | £ | £ |
| Cash flows from operating activities |
| Cash generated from operations | 1 | ( |
) |
| Interest paid | ( |
) | ( |
) |
| Finance costs paid | (140,169 | ) | (190,924 | ) |
| Tax paid | ( |
) |
| Net cash from operating activities | ( |
) |
| Cash flows from investing activities |
| Purchase of tangible fixed assets | ( |
) |
| Net cash from investing activities | ( |
) |
| Cash flows from financing activities |
| Amount introduced by directors | 22,118 | 25,140 |
| Amount withdrawn by directors | (25,140 | ) | (18,312 | ) |
| Equity dividends paid | ( |
) | ( |
) |
| Net cash from financing activities | ( |
) | ( |
) |
| Decrease in cash and cash equivalents | ( |
) | ( |
) |
| Cash and cash equivalents at beginning of year |
2 |
(1,440,367 |
) |
(590,998 |
) |
| Cash and cash equivalents at end of year | 2 | ( |
) | ( |
) |
| Altripan UK Limited (Registered number: 06245964) |
| Notes to the Cash Flow Statement |
| for the year ended 30 November 2025 |
| 1. | RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS |
| 2025 | 2024 |
| £ | £ |
| Profit before taxation |
| Depreciation charges |
| Finance costs | 309,431 | 301,226 |
| 1,397,034 | 1,864,657 |
| Decrease/(increase) in stocks | ( |
) |
| Decrease/(increase) in trade and other debtors | ( |
) |
| (Decrease)/increase in trade and other creditors | ( |
) |
| Cash generated from operations | ( |
) |
| 2. | CASH AND CASH EQUIVALENTS |
| The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts: |
| Year ended 30 November 2025 |
| 30.11.25 | 1.12.24 |
| £ | £ |
| Bank overdrafts | ( |
) | ( |
) |
| Year ended 30 November 2024 |
| 30.11.24 | 1.12.23 |
| £ | £ |
| Bank overdrafts | ( |
) | ( |
) |
| 3. | ANALYSIS OF CHANGES IN NET DEBT |
| At 1.12.24 | Cash flow | At 30.11.25 |
| £ | £ | £ |
| Net cash |
| Bank overdrafts | (1,440,367 | ) | (128,284 | ) | (1,568,651 | ) |
| (1,440,367 | ) | ( |
) | (1,568,651 | ) |
| Total | (1,440,367 | ) | (128,284 | ) | (1,568,651 | ) |
| Altripan UK Limited (Registered number: 06245964) |
| Notes to the Financial Statements |
| for the year ended 30 November 2025 |
| 1. | STATUTORY INFORMATION |
| Altripan UK Limited is a |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| Turnover |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| Tangible fixed assets |
| Fixtures and fittings | - |
| Computer equipment | - |
| Stocks |
| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Foreign currencies |
| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result. |
| With regard to transactions with Altripan NV, these are either translated at the rate at the date of transaction or, where appropriate, exchanged at an agreed rate between the two parties which reflects exchange rate contracts held by Altripan NV. |
| Altripan UK Limited (Registered number: 06245964) |
| Notes to the Financial Statements - continued |
| for the year ended 30 November 2025 |
| 2. | ACCOUNTING POLICIES - continued |
| Hire purchase and leasing commitments |
| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| Financial instruments |
| Financial instruments are classified and accounted for according to the substance of the contractual arrangement. They are classified as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. |
| Invoice discounting |
| The company has entered into an invoice discounting agreement for certain trade debtors. Amounts due from the customer are shown in full in trade debtors, with amounts due to the finance company shown in creditors due within twelve months within other creditors. |
| 3. | EMPLOYEES AND DIRECTORS |
| 2025 | 2024 |
| £ | £ |
| Wages and salaries |
| Social security costs |
| Other pension costs |
| The average number of employees during the year was as follows: |
| 2025 | 2024 |
| Directors | 5 | 4 |
| Sales and Administration | 4 | 5 |
| 2025 | 2024 |
| £ | £ |
| Directors' remuneration |
| Directors' pension contributions to money purchase schemes |
| Altripan UK Limited (Registered number: 06245964) |
| Notes to the Financial Statements - continued |
| for the year ended 30 November 2025 |
| 4. | OPERATING PROFIT |
| The operating profit is stated after charging/(crediting): |
| 2025 | 2024 |
| £ | £ |
| Other operating leases |
| Depreciation - owned assets |
| Auditors' remuneration |
| Auditors' remuneration for non audit work |
| Foreign exchange differences | ( |
) |
| 5. | INTEREST PAYABLE AND SIMILAR EXPENSES |
| 2025 | 2024 |
| £ | £ |
| Bank interest |
| HMRC credit interest | ( |
) |
| Interest on other loans |
| 6. | TAXATION |
| Analysis of the tax charge |
| The tax charge on the profit for the year was as follows: |
| 2025 | 2024 |
| £ | £ |
| Current tax: |
| UK corporation tax |
| Tax on profit |
| Reconciliation of total tax charge included in profit and loss |
| The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below: |
| 2025 | 2024 |
| £ | £ |
| Profit before tax |
| Profit multiplied by the standard rate of corporation tax in the UK of (2024 - |
| Effects of: |
| Expenses not deductible for tax purposes |
| corporation tax rate |
| Deferred tax not provided 2025 | (539 | ) | (911 | ) |
| Deferred tax not provided prior year | 911 | 161 |
| Total tax charge | 285,464 | 389,735 |
| Altripan UK Limited (Registered number: 06245964) |
| Notes to the Financial Statements - continued |
| for the year ended 30 November 2025 |
| 7. | DIVIDENDS |
| 2025 | 2024 |
| £ | £ |
| Ordinary shares of £1 each |
| Interim |
| 8. | TANGIBLE FIXED ASSETS |
| Fixtures |
| and | Computer |
| fittings | equipment | Totals |
| £ | £ | £ |
| Cost |
| At 1 December 2024 |
| and 30 November 2025 |
| Depreciation |
| At 1 December 2024 |
| Charge for year |
| At 30 November 2025 |
| Net book value |
| At 30 November 2025 |
| At 30 November 2024 |
| 9. | STOCKS |
| 2025 | 2024 |
| £ | £ |
| Stocks |
| 10. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2025 | 2024 |
| £ | £ |
| Trade debtors |
| Tax |
| VAT |
| Altripan UK Limited (Registered number: 06245964) |
| Notes to the Financial Statements - continued |
| for the year ended 30 November 2025 |
| 11. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2025 | 2024 |
| £ | £ |
| Bank loans and overdrafts (see note 12) |
| Trade creditors |
| Tax |
| Social security and other taxes |
| VAT | - | 740,581 |
| Other creditors |
| Directors' current accounts | 22,118 | 25,140 |
| Deferred income |
| Accrued expenses |
| 12. | LOANS |
| An analysis of the maturity of loans is given below: |
| 2025 | 2024 |
| £ | £ |
| Amounts falling due within one year or on demand: |
| Bank overdrafts |
| 13. | LEASING AGREEMENTS |
| Minimum lease payments under non-cancellable operating leases fall due as follows: |
| 2025 | 2024 |
| £ | £ |
| Within one year |
| Between one and five years |
| In more than five years |
| 14. | SECURED DEBTS |
| A Customs guarantee has been given to the ING bank N.V for the sum of £260,000. |
| 15. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2025 | 2024 |
| value: | £ | £ |
| Ordinary | £1 | 99 | 99 |
| The company has three designations of shares within ordinary capital which are equal as regards voting, distribution and capital return matters. |
| Altripan UK Limited (Registered number: 06245964) |
| Notes to the Financial Statements - continued |
| for the year ended 30 November 2025 |
| 16. | RESERVES |
| Retained |
| earnings |
| £ |
| At 1 December 2024 |
| Profit for the year |
| Dividends | ( |
) |
| At 30 November 2025 |
| 17. | ULTIMATE PARENT COMPANY |
| Van Steenberge Invest NV (incorporated in Belgium ) is regarded by the directors as being the company's ultimate parent company. |
| 18. | RELATED PARTY DISCLOSURES |
| 2025 | 2024 |
| £ | £ |
| Purchases |
| Haulage, travel expenses, duty and reception costs | 733,884 | 740,539 |
| Interest charges | 66,576 | - |
| Amount due to related party |
| 2025 | 2024 |
| £ | £ |
| Amount due to related party |